✦ LIBER ✦

Effects of interferon-α treatment on hepatitis B virus antigen-specific immunologic responses in patients with chronic hepatitis B

✍ Scribed by Tetsuya Ishikawa; Shinichi Kakumu; Kentaro Yoshioka; Susumu Kurokawa; Atsuhiko Kusakabe; Hirofumi Tahara; Hideo Hirofuji; Masami Kawabe

Book ID: 114796849
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 564 KB
Volume: 13
Category: Article
ISSN: 0106-9543
DOI: 10.1111/j.1600-0676.1993.tb00613.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatitis B virus-specific T cell respon

Hepatitis B virus-specific T cell response in chronic hepatitis B patients treated with lamivudine and interferon-α

✍ Oscar Pontesilli; Andeltje B. Van Nunen; Debby Van Riel; Patrizia Carotenuto; Hu 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 207 KB

Absence of hepatitis B virus precore mut

Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to interferon-α

✍ Jianye Xu; David Brown; Tim Harrison; Yue Lin; Geoffrey Dusheiko 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 614 KB

Precore defective HBV mutants may gradually prevail because of immune selection and explain spontaneous seroconversion from HBeAg to anti-HBe in HBV carriers. We have analyzed whether the presence of precore HBV mutants is a determinant of responsiveness to interferon-a therapy. Fifteen carriers (ni

Hepatitis B virus-specific cytotoxic T l

Hepatitis B virus-specific cytotoxic T lymphocyte responses in patients with acute and chronic hepatitis B virus infection

✍ Els Van Hecke; Joseph Paradijs; Chantal Molitor; Carine Bastin; Pietro Pala; Mon 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 832 KB

A randomized controlled trial of thymosi

A randomized controlled trial of thymosin-α1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody—and hepatitis B virus DNA—positive chronic hepatitis B

✍ P Andreone; C Cursaro; A Gramenzi; C Zavaglia; I Rezakovic; E Altomare; R Severi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 1 views

ment for anti-HBe-positive chronic hepatitis. The benefit It has recently been shown that thymosin-a 1 (T-a 1 ), a of this agent in producing long-term inhibition of HBV synthetic polypeptide of thymic origin, is able to proreplication must be confirmed by future trials. (HEPAmote disease remission

Potent hepatitis B surface antigen respo

Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog

✍ Xinyue Chen; Zhenhuan Cao; Yali Liu; Hongwei Zhang; Yonghong Zhang; Lina Ma; Yi 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 764 KB

Efficacy of lamivudine in patients with

Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB

✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60